Supernus Pharmaceuticals, Inc.
SUPN
Rank in Stocks
#6738
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Share Price
$27.62
Last synced: 2026-11-09
Market Cap
$1.61B
Change (1 day)
5.58%
Change (1 year)
-40.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Supernus Pharmaceuticals, Inc. (SUPN)
Category
Healthcare
EPS for Supernus Pharmaceuticals, Inc. (SUPN)
EPS as of September 2026 TTM: $3.66
According to Supernus Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $3.66. At the end of 2025 the company had an EPS of $1.68, an increase over its 2024 EPS of $1.34.
EPS history for Supernus Pharmaceuticals, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $3.66 | 117.86% |
| 2025 | $1.68 | 25.37% |
| 2024 | $1.34 | 5,460.17% |
| 2023 | $0.02 | -97.87% |
| 2022 | $1.13 | 11.88% |
| 2021 | $1.01 | -58.09% |
| 2020 | $2.41 | 11.57% |
| 2019 | $2.16 | 1.41% |
| 2018 | $2.13 | 88.50% |
| 2017 | $1.13 | -38.59% |
| 2016 | $1.84 | 534.48% |
| 2015 | $0.29 | -38.30% |
| 2014 | $0.47 | -116.21% |
| 2013 | $-2.90 | 9.43% |
| 2012 | $-2.65 | -172.80% |
| 2011 | $3.64 | -230.94% |
| 2010 | $-2.78 | 1,223.81% |
| 2009 | $-0.21 | -91.32% |
| 2008 | $-2.42 | 93.60% |
| 2007 | $-1.25 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | 77.63% |
DE
|
|
| $6.08 | 66.05% |
DE
|
|
| $1.55 | -57.63% |
JP
|
|
| $3.66 | 0.00% |
CH
|
|
| $0.45 | -87.70% |
IL
|
Questions about Supernus Pharmaceuticals, Inc.'s earnings per share (EPS)
What is Supernus Pharmaceuticals, Inc.'s earnings per share (EPS)?
Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $3.66, as of Sep 2026.
What was Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?
In 2025, Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) was $1.68, 25.37% more than in 2024 ($1.34).
How has Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) went from $2.41 to $1.68, an average decline of 6.96% a year.
How does Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?
Supernus Pharmaceuticals, Inc.'s earnings per share (EPS) ($3.66) is higher than that of 2 of the 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.